Detrusitol SR

Detrusitol SR





Zuellig Pharma
Concise Prescribing Info
Tolterodine tartrate
Overactive bladder w/ symptoms of urge urinary incontinence, urgency & frequency.
Dosage/Direction for Use
4 mg once daily, may be decreased to 2 mg once daily depending on response & tolerability. Mild to moderate hepatic or severe renal impairment 2 mg once daily.
May be taken with or without food: Swallow whole, do not chew/crush.
Hypersensitivity to tolterodine tartrate, fesoterodine fumarate. Urinary & gastric retention, uncontrolled narrow angle glaucoma.
Special Precautions
Discontinue use if difficulty in breathing, upper airway obstruction or fall in BP & anticholinergic CNS effects occur. Patients w/ clinically significant bladder outflow obstruction at risk of urinary retention, GI obstructive disorders at risk of gastric retention, decreased GI motility or patients being treated for narrow-angle glaucoma. Myasthenia gravis; history of QT prolongation. Concomitant use w/ class IA or III antiarrhythmics. May affect ability to drive or operate heavy machinery. Not recommended in severe hepatic impairment & CrCl <10 mL/min. Pregnancy & lactation. Ped.
Adverse Reactions
Dry mouth; headache, fatigue; dizziness; constipation, abdominal pain, dyspepsia; xerophthalmia, abnormal vision; somnolence, anxiety; sinusitis; dysuria.
Drug Interactions
Increased mean Cmax & AUC w/ potent CYP3A4 inhibitors eg, ketoconazole, itraconazole, clarithromycin, ritonavir. Other anticholinergic/antimuscarinic agents.
ATC Classification
G04BD07 - tolterodine ; Belongs to the class of urinary antispasmodics.
Detrusitol SR ER cap 4 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in